| Drug Type Bispecific T-cell Engager (BiTE) | 
| Synonyms ABS 103(Amberstone Biosciences), ABS103(Amberstone Biosciences) | 
| Target | 
| Action stimulants, agonists | 
| Mechanism CD3 stimulants(T cell surface glycoprotein CD3 stimulants), Tumor-associated antigen agonists(Tumor-associated antigen agonists) | 
| Therapeutic Areas | 
| Active Indication- | 
| Inactive Indication | 
| Originator Organization | 
| Active Organization- | 
| Inactive Organization | 
| License Organization- | 
| Drug Highest PhaseDiscontinuedPreclinical | 
| First Approval Date- | 
| Regulation- | 
| Indication | Highest Phase | Country/Location | Organization | Date | 
|---|---|---|---|---|
| Neoplasms | Preclinical | United States  | 15 May 2024 | 






